flora peyvandi/X
Dec 8, 2025, 07:42
Flora Peyvandi: Anti-emicizumab Antibodies and Their Relevance in Clinical Practice
Flora Peyvandi, Professor of Internal Medicine at the University of Milan and former President of ISTH, shared a post on X:
“The development of anti-emicizumab antibodies is a rare event, particularly those with neutralizing activity. Routine monitoring should be reserved only for patients with clinical manifestations of bleeding when therapy failure is suspected.”
Title: Anti-emicizumab antibodies and their relevance in clinical practice
Authors: Carla Valsecchi, Lucia Schiavone, Sara Arcudi, Adriana Torri, Cristina Novembrino, Flora Peyvandi
Read the full article.
More posts featuring Flora Peyvandi on Hemostasis Today.
-
May 13, 2026, 15:38International Journal of Stroke: Oral Anticoagulants and DOAC–Antiplatelet Therapy Are Associated with Increased Major Bleeding Risk
-
May 13, 2026, 15:19Papa Heme։ Causes of Isolated Prolonged aPTT Without Bleeding
-
May 13, 2026, 15:10Wolfgang Miesbach: Rethinking Bleeding Risk in Anticoagulation
-
May 13, 2026, 15:09Veronica Sanchez: Better Cardiovascular Health Helps Lower Heart Attack Risk
-
May 13, 2026, 15:07Tung Nguyen Thanh: New Perspective on Thrombosis in Hematological Malignancies in Vietnam
-
May 13, 2026, 15:03Haji Siyamuddin Ansari: The Key Difference Between Plasma and Serum
-
May 13, 2026, 14:45Masoabi Sefojane: The Cost of a 35-Year Diagnosis Delay
-
May 13, 2026, 14:39Ahmed Mohsen: Managing DVT During Pregnancy and Lactation
-
May 13, 2026, 14:38The Coffee Shop Origins of Factor V Leiden – ISTH